STAMFORD, Conn.—FUJIFILM Medical Systems U.S.A., Inc., a leading provider of diagnostic imaging and medical informatics solutions, today introduced the FCT Embrace. Powered by Analogic, the FCT Embrace is the world’s first 85cm wide bore computed tomography (CT) imaging unitwith 64 or 128 slice configurations. Optimized for both oncology and radiology applications, the FCT Embrace, combined with other market-leading oncology solutions, offers enhanced and efficient CT Simulation with radiotherapy treatment planning capabilities. The unveiling at booth #3063 during the 2018 American Society for Radiation Oncology (ASTRO) Annual Meeting marks Fujifilm’s entry into the CT market, expanding its end-to-end diagnostic imaging product portfolio which is recognized for exceptional imaging at low dose.

"Despite the help offered by this classification system, the BI-RADS 3 category includes probably benign lesions whose management has been widely debated in the literature," wrote Chiara Adriana Pistolese, from the department of diagnostic imaging at Tor Vergata University Rome in Italy, and colleagues.

Researchers have found diffusion-weighted magnetic resonance imaging (DWI) or gadolinium-enhanced T1-weighted volumetric interpolated breath-hold examination (VIBE) sequences are the most efficient MRI sequences for prostate cancer diagnosis, according to new research published online on Oct. 17 in the American Journal of Roentgenology.

A new study found that rates of supplemental screening among black women with dense breasts increased after the passage of statewide mandatory breast density notification laws, according to research published Oct. 18 in the Journal of the American College of Radiology.

At the 60th annual meeting of the American Society for Radiation Oncology (ASTRO), Oct. 21-24 at the Henry B. Gonzalez Convention Center in San Antonio, Siemens Healthineers unveils the MAGNETOM RT Pro edition for MAGNETOM Sola – a version of the company’s new 1.5 Tesla (1.5T) magnetic resonance imaging (MRI) scanner that is designed for assistance in radiation therapy (RT) treatment planning. In addition to BioMatrix technology, which addresses patients’ anatomical and physiological differences to overcome unwanted exam variability, the new scanner includes hardware and software that supports optimal treatment planning.

Continuing its efforts to empower clinicians and patients in their fight against breast cancer, GE Healthcare today launched the Invenia Automated Breast Ultrasound (ABUS) 2.0 in the United States.

A $1.6 million, four-year grant from the National Cancer Institute of the National Institutes of Health (NIH) was awarded to a researcher from Tulane University in Louisiana to develop a prostate cancer scanner that can check whether all traces of cancer have been removed after surgery, according to The Associated Press.

The University of Texas at Arlington (UTA) was awarded U.S. and international patents on a nanoparticle that can be activated by x-ray or ultrasound and kill multiple cancers without harming healthy surrounding tissues.